A Mutiple Dose, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous AMG 108 in Patients With Type 2 Diabetes Mellitus
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 12 Sep 2018
At a glance
- Drugs MEDI 8968 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Amgen
- 31 Aug 2018 Biomarkers information updated
- 05 Feb 2009 Actual initiation date (Jun 2008) added as reported by ClinicalTrials.gov.
- 05 Feb 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.